MX2016010411A - Compuestos agonistas de gpr142. - Google Patents

Compuestos agonistas de gpr142.

Info

Publication number
MX2016010411A
MX2016010411A MX2016010411A MX2016010411A MX2016010411A MX 2016010411 A MX2016010411 A MX 2016010411A MX 2016010411 A MX2016010411 A MX 2016010411A MX 2016010411 A MX2016010411 A MX 2016010411A MX 2016010411 A MX2016010411 A MX 2016010411A
Authority
MX
Mexico
Prior art keywords
agonist compounds
group
gpr142 agonist
gpr142
ch2chf2
Prior art date
Application number
MX2016010411A
Other languages
English (en)
Inventor
Ma Tianwei
Emily ZENG Mi
Long Hu Zhi
Zhu LIU Lian
Zhou Jingye
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2016010411A publication Critical patent/MX2016010411A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

La presente invención se refiere a compuestos de la fórmula (ver Fórmula) en donde R se selecciona a partir del grupo que consiste de CH3, CH(CH3)2, CH2CN, CH2CHF2, CH2CF3, (ver Fórmula) CH2CH2OCH3 y CH2C(O)OCH(CH3)2; R1 se selecciona a partir del grupo que consiste de CF3, OCF3 y CI; R2 se selecciona a partir del grupo que consiste de H y F; o una sal del mismo farmacéuticamente aceptable.
MX2016010411A 2014-02-14 2015-01-22 Compuestos agonistas de gpr142. MX2016010411A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2014/072083 WO2015120610A1 (en) 2014-02-14 2014-02-14 Gpr142 agonist compound
PCT/CN2015/071286 WO2015120768A1 (en) 2014-02-14 2015-01-22 Gpr142 agonist compounds

Publications (1)

Publication Number Publication Date
MX2016010411A true MX2016010411A (es) 2016-10-17

Family

ID=53799520

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010411A MX2016010411A (es) 2014-02-14 2015-01-22 Compuestos agonistas de gpr142.

Country Status (10)

Country Link
US (1) US9861613B2 (es)
EP (1) EP3105207B1 (es)
JP (1) JP6298172B2 (es)
CN (1) CN106170478B (es)
AU (1) AU2015218135B2 (es)
CA (1) CA2935109A1 (es)
EA (1) EA201691265A1 (es)
ES (1) ES2693545T3 (es)
MX (1) MX2016010411A (es)
WO (2) WO2015120610A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016138631A1 (en) 2015-03-03 2016-09-09 Eli Lilly And Company Imidazo benzamide compounds
WO2018014337A1 (en) * 2016-07-22 2018-01-25 Eli Lilly And Company 3-Chloro-N- [ (1R, 3S) -3- [5- (3, 5-dimethylimidazol-4-yl) -4H-1, 2, 4-triazol-3-yl] cyclohexyl] -N-methyl-benzamide
JP7391055B2 (ja) 2018-07-04 2023-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｐｒ１４２アゴニストとしてのトリアゾールベンズアミド誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ548208A (en) * 2004-02-12 2010-09-30 Transtech Pharma Inc Substituted azole derivatives, compositions, and methods of use
US20070032475A1 (en) * 2005-04-15 2007-02-08 Ye Xiaocong M Novel compounds useful for bradykinin B1 receptor antagonism
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
US20090270394A1 (en) * 2008-04-28 2009-10-29 Galemmo Jr Robert Cyclylamine derivatives as calcium channel blockers
US8188098B2 (en) * 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
WO2010101247A1 (ja) * 2009-03-05 2010-09-10 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するシクロヘキサン誘導体
AR079170A1 (es) * 2009-12-10 2011-12-28 Lilly Co Eli Compuesto de ciclopropil-benzamida-imidazo-benzazepina inhibidor de diacil-glicerol aciltransferasa, sal del mismo, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de obesidad o para mejorar la sensibilidad a insulina y compuesto intermedio par

Also Published As

Publication number Publication date
CA2935109A1 (en) 2015-08-20
EP3105207A4 (en) 2017-06-21
EP3105207A1 (en) 2016-12-21
WO2015120610A1 (en) 2015-08-20
EP3105207B1 (en) 2018-08-22
ES2693545T3 (es) 2018-12-12
EA201691265A1 (ru) 2016-11-30
AU2015218135B2 (en) 2017-06-08
JP6298172B2 (ja) 2018-03-20
CN106170478B (zh) 2019-04-09
US9861613B2 (en) 2018-01-09
JP2017505797A (ja) 2017-02-23
CN106170478A (zh) 2016-11-30
AU2015218135A1 (en) 2016-07-14
WO2015120768A1 (en) 2015-08-20
US20170165234A1 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
PH12019501842A1 (en) Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
PH12016501007A1 (en) Substituted benzamides and methods of use thereof
NZ732657A (en) Picolinamides with fungicidal activity and other related compounds
SG10201809518QA (en) Processes of preparing a jak1 inhibitor and new forms thereto
TW201613911A (en) Heterocyclic compounds and uses thereof
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
MX2016011992A (es) Derivados de piperidina-diona.
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
MX2018001430A (es) Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
WO2014144545A3 (en) Substituted benzoxazoles and methods of use thereof
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
TN2018000020A1 (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
PH12016501517B1 (en) Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
MA39956A (fr) Analogues du benzomorphane et leur utilisation
MX2017002214A (es) Proceso para la preparacion de 5-fluoro-1h-pirazoles partiendo de hexafluoropropeno.
MX2016010973A (es) Compuestos de aminocarbonilcarbamato.
MX2015017156A (es) Inhibidores de bace.
MX2015015562A (es) Dihidropiridinona como inhibidores de monoacilglicerol aciltransferasa 2.
MX2016008909A (es) Compuestos de isopropil triazolo piridina.
MX2019010980A (es) Antagonistas del receptor opioide kappa y productos y metodos relacionados al mismo.
MX2016015543A (es) Proceso para la preparacion de 5-fluoro-1h-pirazoles a partir de hexafluoropropeno.
NZ739518A (en) Compounds useful for inhibiting ror-gamma-t
EA201892235A1 (ru) Гранулированная композиция для перорального применения
MX2016010411A (es) Compuestos agonistas de gpr142.